Erdem FŞ et al., 2026-11-17: Single-centre Turkish pediatric series of 24 patients in which methylene blue lowered post-treatment methemoglobin more than intravenous ascorbic acid, but the relative reduction was not significantly different.
Post-treatment methemoglobin was lower with methylene blue (2.6% vs. 7.8%; p = 0.024), whereas relative reduction did not differ significantly (88.8% vs. 72.8%; p = 0.118).
Erdem FŞ et al., 2026-11-17: Single-centre Turkish pediatric series of 24 patients in which methylene blue lowered post-treatment methemoglobin more than intravenous ascorbic acid, but the relative reduction was not significantly different. C3. Study type: single-centre retrospective study (Ankara Etlik City Hospital, Turkey), N=24, Nov 2022 – Nov 2025. Median age 4 months; drug exposure 19 cases (lidocaine 10, prilocaine 7, mostly circumcision-related); 5 without oxidant exposure, 4 of whom had pathogenic or likely pathogenic CYB5R3 variants. 11 received methylene blue, 13 IV ascorbic acid; doses not stated in the abstract text captured. Funder and conflicts: not stated in the PubMed record. Comparator: intravenous ascorbic acid. SUPPORTS C3 as a series of methylene-blue-treated acquired cases; the advantage over ascorbic acid was limited to absolute post-treatment level. Study type: controlled study.
